NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

Not Yet RecruitingPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Alzheimer's Disease

Interventions: RO7568282, Placebo

This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).

Eligibility overview

Sex: ALL

Age: 50 Years to 90 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
* Mild cognitive impairment (MCI) or mild dementia due to AD
* Able to swallow whole capsules
* Body mass index (BMI) within the range of 18-34 kilograms per square metre (kg/m²) (at screening)
* Availability of an appropriate study partner

Exclusion Criteria:

* Any evidence of a condition other than AD that may affect cognition
* Participants must not have unstable or clinically significant cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant electrocardiogram (ECG) abnormalities
* History or presence of clinically significant cerebrovascular disease
* Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI)

Note: Other protocol-defined inclusion/exclusion criteria may apply.